Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians can combine, mix, or adjust the ingredients of a medication — to meet ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...